Compound · clinical trials

Rilvegostomig clinical trials

Also listed in trial records as AZD2936, AZD8205 and AZD2936, AZD8205 and AZD5305 (saruparib) and AZD2936, Other Name: AZD2936

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 34 trials in our USA, Spain, South Korea, Taiwan, Japan, China, Italy, Canada, UK, France, Poland, Belgium, Turkey, Brazil, Australia, Germany, Netherlands, India, Austria, Switzerland, Denmark, Singapore, Ireland, Portugal, Israel, Norway, Sweden and Czechia registers that name Rilvegostomig as an intervention. Synced 9 Nov 2026

34Current trials

24Recruiting now

6Lead sponsors

28Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Rilvegostomig is named as an intervention in 34 current clinical trials in our USA, Spain, South Korea, Taiwan, Japan, China, Italy, Canada, UK, France, Poland, Belgium, Turkey, Brazil, Australia, Germany, Netherlands, India, Austria, Switzerland, Denmark, Singapore, Ireland, Portugal, Israel, Norway, Sweden and Czechia registers. 24 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (29). The most-studied condition is Gastric Cancer. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials.

How Rilvegostomig works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

Biliary tract cancerPhase 3
Endometrial cancerPhase 3
Esophageal adenocarcinomaPhase 3
Gastric adenocarcinomaPhase 3
Gastroesophageal junction adenocarcinomaPhase 3
Hepatocellular carcinomaPhase 3
Non-small cell lung carcinomaPhase 3
CancerPhase 2
Colorectal cancerPhase 2
Colorectal carcinomaPhase 2

21 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314706, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Rilvegostomig

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting2471%
Not yet open26%
Active, closed824%

Trials by phase

Phase 31338%
Phase 21132%
Phase 1/2515%
Phase 1412%
Early Phase 113%

Clinical trials of Rilvegostomig

34 trials

Study	Phase	Status	Lead sponsor	Registers
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations NCT06357533 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, Spain, Italy, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738 · Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277 · Carcinoma, Non-Small Cell Lung	Phase 3	Recruiting	AstraZeneca	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Switzerland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma NCT06921785 · Hepatocellular Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) NCT07221253 · Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer NCT05061550 · Non-small Cell Lung Cancer	Phase 2	Recruiting	AstraZeneca	Ireland, USA, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, South Korea, Taiwan
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC NCT05414032 · ClinicalTrials.gov ↗ · Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)	Phase 2	Recruiting	University Health Network, Toronto	Canada
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT05702229 · Gastric Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Japan, South Korea, Taiwan
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer NCT06630130 · ClinicalTrials.gov ↗ · Stomach Neoplasms	Phase 2	Recruiting	Jeeyun Lee	South Korea
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712 · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Italy, Poland, Turkey, Canada, Japan, Taiwan
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) NCT07098338 · Non-Small Cell Lung Cancer	Phase 2	Recruiting	AstraZeneca	USA, China, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Singapore, Australia
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies NCT05123482 · Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, Spain, Italy, Netherlands, Belgium, Poland, Canada, Japan, South Korea, Taiwan, Australia
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors NCT06005493 · Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, France, Netherlands, Japan, South Korea, Taiwan
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782 · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	AstraZeneca	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 · ClinicalTrials.gov ↗ · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)	Phase 1/2	Recruiting	AstraZeneca	USA, Japan, South Korea, Australia
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 1	Recruiting	AstraZeneca	USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy NCT07161414 · Advanced Solid Tumors	Phase 1	Recruiting	AstraZeneca	UK, USA, Spain, South Korea
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma NCT07128290 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Federation Francophone de Cancerologie Digestive	France
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project) NCT07788664 · Advanced Gastric Cancer	Phase 2	Not yet open	Vall d'Hebron Institute of Oncology	Spain
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) NCT06109779 · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features NCT06564844 · Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, Turkey, Canada, Brazil, Japan, Taiwan
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer NCT05775159 · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Spain, Italy, Japan, South Korea, Taiwan
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC NCT04995523 · Non-Small-Cell Lung Carcinoma	Phase 1/2	Active, closed	AstraZeneca	USA, China, France, Spain, Netherlands, Belgium, Denmark, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC NCT03819465 · Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AstraZeneca	USA, Spain, Belgium, Poland, Austria, South Korea, Taiwan
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer NCT04612751 · Advanced or Metastatic NSCLC	Phase 1	Active, closed	AstraZeneca	USA, Spain, Italy, Belgium, Poland, Turkey, Japan, Taiwan
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies NCT04541108 · Solid Tumor	Early Phase 1	Active, closed	Presage Biosciences	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Rilvegostomig in the EU trials register (CTIS)

4 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rilvegostomig. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04). 2025-525030-57-00 · Neoplasms	Phase 3	Ongoing	AstraZeneca AB	Italy, Poland, Spain + 2 more
Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project) 2026-525620-23-00 · Neoplasms	Phase 2	Authorised	Vall D Hebron Institute Of Oncology	Spain
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS) 2025-523599-21-00 · Neoplasms	Phase 2	Authorised	AstraZeneca AB	Spain, Germany
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) 2024-519786-22-01 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	AstraZeneca AB	Germany, Spain, France + 4 more

Conditions studied with Rilvegostomig

34 conditions

Gastric Cancer5 Non-small Cell Lung Cancer4 Biliary Tract Cancer4 Endometrial Cancer3 Hepatocellular Carcinoma2 Ovarian Cancer2 Non-Small Cell Lung Cancer2 Gastroesophageal Junction Adenocarcinoma2 Carcinoma, Non-Small Cell Lung1 Breast Cancer1Biliary Tract Carcinoma1High-risk Muscle Invasive Urothelial Carcinoma1

All 34 conditions

Condition (as registered)	Trials
Gastric Cancer	5
Non-small Cell Lung Cancer	4
Biliary Tract Cancer	4
Endometrial Cancer	3
Hepatocellular Carcinoma	2
Ovarian Cancer	2
Non-Small Cell Lung Cancer	2
Gastroesophageal Junction Adenocarcinoma	2
Carcinoma, Non-Small Cell Lung	1
Breast Cancer	1
Biliary Tract Carcinoma	1
High-risk Muscle Invasive Urothelial Carcinoma	1
Esophageal Cancer	1
Gastro-esophageal Junction Cancer	1
Pancreatic Ductal Adenocarcinoma	1
Esophageal Adenocarcinoma	1
Metastatic Castration-resistant Prostate Cancer	1
HER2-positive Gastric Cancer	1
Advanced Solid Tumors	1
Non-squamous Non-small Cell Lung Cancer	1
Gastroesophageal Adenocarcinoma	1
Melanoma	1
Squamous Cell Carcinoma (Skin)	1
Renal Cell Carcinoma	1
Locally Advanced or Metastatic Non-Small Cell Lung Cancer	1
Non-Small-Cell Lung Carcinoma	1
Advanced or Metastatic NSCLC	1
Advanced or Metastatic Non-small Cell Lung Cancer	1
Solid Tumor	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Advanced Gastric Cancer	1
Stomach Neoplasms	1
Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	30	22
Clinical trials in Spain	27	20
Clinical trials in South Korea	27	22
Clinical trials in Taiwan	26	19
Clinical trials in Japan	25	19
Clinical trials in China	23	19
Clinical trials in Italy	22	18
Clinical trials in Canada	21	18
Clinical trials in UK	20	17
Clinical trials in France	19	16
Clinical trials in Poland	19	15
Clinical trials in Belgium	17	13
Clinical trials in Turkey	17	14
Clinical trials in Brazil	17	13
Clinical trials in Australia	17	15
Clinical trials in Germany	15	13
Clinical trials in Netherlands	14	12
Clinical trials in India	10	9
Clinical trials in Austria	7	6
Clinical trials in Switzerland	3	3
Clinical trials in Denmark	3	1
Clinical trials in Singapore	3	3
Clinical trials in Ireland	2	2
Clinical trials in Portugal	2	2
Clinical trials in Israel	2	2
Clinical trials in Norway	2	1
Clinical trials in Sweden	1	1
Clinical trials in Czechia	1	1
EU register (CTIS)	4	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Rilvegostomig trials

How many clinical trials are testing Rilvegostomig?

34 current trials in our USA, Spain, South Korea, Taiwan, Japan, China, Italy, Canada, UK, France, Poland, Belgium, Turkey, Brazil, Australia, Germany, Netherlands, India, Austria, Switzerland, Denmark, Singapore, Ireland, Portugal, Israel, Norway, Sweden and Czechia registers name Rilvegostomig (also registered as AZD2936) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Rilvegostomig trials recruiting patients?

Yes. 24 of the 34 trials are recruiting: 22 with sites in USA, 20 with sites in Spain, 22 with sites in South Korea, 19 with sites in Taiwan, 19 with sites in Japan, 19 with sites in China, 18 with sites in Italy, 18 with sites in Canada, 17 with sites in UK, 16 with sites in France, 15 with sites in Poland, 13 with sites in Belgium, 14 with sites in Turkey, 13 with sites in Brazil, 15 with sites in Australia, 13 with sites in Germany, 12 with sites in Netherlands, 9 with sites in India, 6 with sites in Austria, 3 with sites in Switzerland, 1 with sites in Denmark, 3 with sites in Singapore, 2 with sites in Ireland, 2 with sites in Portugal, 2 with sites in Israel, 1 with sites in Norway, 1 with sites in Sweden and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Rilvegostomig clinical trials?

AstraZeneca (29), Presage Biosciences (1), Federation Francophone de Cancerologie Digestive (1) and Vall d'Hebron Institute of Oncology (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Rilvegostomig clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rilvegostomig works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rilvegostomig works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rilvegostomig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.